Marimed (MRMD) EBIT Margin (2011 - 2026)

Marimed (MRMD) has reported EBIT Margin for 16 consecutive years, with 1.0% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin fell 157.0% year-over-year to 1.0% in Q2 2026; TTM through Jun 2026 was 1.45%, a 144.0% decrease from a year earlier, with the FY2025 full-year figure at 1.76%, down 342.0% from the prior year.
• EBIT Margin was 1.0% for Q2 2026 at Marimed, up from 0.32% in the prior quarter.
• Over five years, EBIT Margin peaked at 22.53% in Q1 2022 and troughed at 10.86% in Q4 2025.
• A 5-year average of 5.71% and a median of 4.63% in 2024 frame the typical range for EBIT Margin.
• The widest YoY moves for EBIT Margin: up 475 bps in 2022, down 2322 bps in 2022.
• Over 5 years, EBIT Margin stood at 8.62% in 2022, then slipped by 28 bps to 6.2% in 2023, then sank by 161 bps to 3.77% in 2024, then slumped by 188 bps to 10.86% in 2025, then jumped by 109 bps to 1.0% in 2026.
• The last three EBIT Margin figures came in at 1.0% (Q2 2026), 0.32% (Q1 2026), and 10.86% (Q4 2025), per Business Quant data.